Advertisement

Organisation › Details
Enara Bio Ltd.
Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors. Our internal focus is developing TCR-directed immunotherapies against Dark Antigen targets that are highly prevalent and homogenously expressed across solid tumors. Our partner, Boehringer Ingelheim, is combining multiple Dark Antigens to create off-the-shelf therapeutic cancer vaccines. Based in Oxford, UK, Enara Bio is backed by a strong syndicate of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. *
![]() |
Start | 2020-06-03 renamed |
Group | Enara Bio (Group) | |
Predecessor | Ervaxx Ltd. | |
![]() |
Industry | cancer vaccine |
Industry 2 | EDAPT™ platform (dark antigen identification) | |
![]() |
Person | Pojasek, Kevin (Ervaxx 201911 CEO) |
Person 2 | Ashrafian, Houman (SV Health Investors 201810 Partner) | |
![]() |
Region | London, Greater London |
Country | United Kingdom (GB) | |
Street | 1 Robert Robinson Avenue Oxford Science Park, The Magdalen Centre | |
City | OX4 4GA Oxford, Oxfordshire | |
Address record changed: 2024-10-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Enara Bio Ltd.. (10/3/24). "Press Release: Enara Bio Raises $32.5 Million Series B Financing to Advance First-in-Class Pipeline of TCR-based Immunotherapies Targeting Novel Dark Antigens". Oxford. | ||
Record changed: 2024-10-06 |
Advertisement

More documents for Enara Bio (Group)
- [1] Enara Bio Ltd.. (10/3/24). "Press Release: Enara Bio Raises $32.5 Million Series B Financing to Advance First-in-Class Pipeline of TCR-based Immunotherapies Targeting Novel Dark Antigens". Oxford....
- [2] Enara Bio Ltd.. (1/4/24). "Press Release: Boehringer Ingelheim Licenses Multiple Dark Antigens from Enara Bio to Develop Off-the-Shelf Immunotherapies for Non-small Cell Lung Cancer (NSCLC)". Oxford....
- [3] Enara Bio Ltd.. (9/28/21). "Press Release: Enara Bio Announces the Appointment of Highly Experienced Biotech Executive Dr. Robert Ang to its Board of Directors". Oxford....
- [4] Boehringer Ingelheim. (1/12/21). "Press Release: Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies". Ingelheim, Oxford & London....
- [5] Enara Bio Ltd.. (12/9/20). "Press Release: Enara Bio Relocates to The Oxford Science Park’s Newest Facility to Expand R&D Capabilities in the Search for Novel Vancer Immunotherapies". Oxford & London....
- [6] Ervaxx Ltd.. (1/24/20). "Press Release: Ervaxx and Cardiff University Enter Collaboration to Develop novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens". London....
- [7] Ervaxx Ltd.. (11/6/19). "Press Release: Ervaxx Launches to Pioneer the Use of Dark Antigens for the Development of Off-the-Shelf Cancer Vaccines and T-cell Receptor-based Immunotherapies". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top